Effectiveness of a specific follow up program for the management of the mental components of Post-ICU Syndrome and Chronic Pain After COVID-19 Infection: Results from the PAIN-COVID Randomized Clinical Trial.
COVID-19
Critical illness survivors
Supervivientes de enfermedad crítica
calidad de vida
chronic ICU-related pain
dolor crónico relacionado con la UCI
ensayo controlado aleatorizado
post ICU syndrome
quality of life
randomized control trial
síndrome post-UCI
Journal
Revista espanola de anestesiologia y reanimacion
ISSN: 2341-1929
Titre abrégé: Rev Esp Anestesiol Reanim (Engl Ed)
Pays: Spain
ID NLM: 101778594
Informations de publication
Date de publication:
17 Jan 2024
17 Jan 2024
Historique:
medline:
20
1
2024
pubmed:
20
1
2024
entrez:
19
1
2024
Statut:
aheadofprint
Résumé
Critical COVID-19 survivors are at risk of developing Post-intensive Care Syndrome (PICS) and Chronic ICU-Related Pain (CIRP). We determined whether a specific care program improves the quality of life (QoL) of patients at risk of developing PICS and CIRP after COVID-19 disease. The PAIN-COVID trial was a parallel-group, single-centre, single-blinded, randomized controlled trial. The intervention consisted of a follow up program, patient education on PICS and pain, and a psychological intervention based on Rehm's self-control model in patients with abnormal depression scores (>=8) in the Hospital Anxiety and Depression Scale (HADS) at the baseline visit. QoL was evaluated with the 5-level EQ 5D (EQ 5D 5 L), mood disorders with the HADS, post-traumatic stress disorder (PTSD) with the PCL-5 checklist, and pain with the Brief Pain Inventory short form, the Douleur Neuropathique 4 questionnaire, and the Pain Catastrophizing Scale. The primary outcome was to determine if the program was superior to standard-of-care on the EQ visual analogue scale (VAS) at 6 months after the baseline visit. The secondary outcomes were EQ VAS at 3 months, and EQ index, CIRP incidence and characteristics, and anxiety, depression, and PTSD at 3 and 6 months after baseline visits. This program was not superior to standard care in improving QoL in critical COVID-19 survivors as measured by the EQ VAS. However, our data can help establish better strategies for the study and management of PICS and CIRP in this population. # NCT04394169, registered on 5/19/2020.
Sections du résumé
BACKGROUND
BACKGROUND
Critical COVID-19 survivors are at risk of developing Post-intensive Care Syndrome (PICS) and Chronic ICU-Related Pain (CIRP). We determined whether a specific care program improves the quality of life (QoL) of patients at risk of developing PICS and CIRP after COVID-19 disease.
METHODS
METHODS
The PAIN-COVID trial was a parallel-group, single-centre, single-blinded, randomized controlled trial. The intervention consisted of a follow up program, patient education on PICS and pain, and a psychological intervention based on Rehm's self-control model in patients with abnormal depression scores (>=8) in the Hospital Anxiety and Depression Scale (HADS) at the baseline visit. QoL was evaluated with the 5-level EQ 5D (EQ 5D 5 L), mood disorders with the HADS, post-traumatic stress disorder (PTSD) with the PCL-5 checklist, and pain with the Brief Pain Inventory short form, the Douleur Neuropathique 4 questionnaire, and the Pain Catastrophizing Scale. The primary outcome was to determine if the program was superior to standard-of-care on the EQ visual analogue scale (VAS) at 6 months after the baseline visit. The secondary outcomes were EQ VAS at 3 months, and EQ index, CIRP incidence and characteristics, and anxiety, depression, and PTSD at 3 and 6 months after baseline visits.
CONCLUSIONS
CONCLUSIONS
This program was not superior to standard care in improving QoL in critical COVID-19 survivors as measured by the EQ VAS. However, our data can help establish better strategies for the study and management of PICS and CIRP in this population.
TRIAL REGISTRATION
BACKGROUND
# NCT04394169, registered on 5/19/2020.
Identifiants
pubmed: 38242358
pii: S2341-1929(23)00206-8
doi: 10.1016/j.redare.2023.12.009
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT04394169']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024. Publicado por Elsevier España, S.L.U.